

## DAA-Experienced (Including NS5A Inhibitors Except Glecaprevir/Pibrentasvir Failures), Genotype 3 Patients, With or Without Compensated Cirrhosis

Recommended regimens by evidence level for:

### Sofosbuvir + Ribavirin-Experienced ( $\pm$ Peginterferon), Genotype 3 Patients, With or Without Compensated Cirrhosis<sup>a</sup>

| RECOMMENDED   | DURATION | RATING |
|---|----------|--------|
| Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100mg) | 12 weeks | I, B   |
| Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>b</sup>       | 16 weeks | IIb, B |

<sup>a</sup> For [decompensated cirrhosis](#), please refer to the appropriate section.

<sup>b</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

Recommended regimen for:

### DAA-Experienced (Including NS5A Inhibitors Except Glecaprevir/Pibrentasvir Failures), Genotype 3 Patients, With or Without Compensated Cirrhosis<sup>a</sup>

| RECOMMENDED  | DURATION | RATING |
|--|----------|--------|
| Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg)                   | 12 weeks | I, A   |
| <hr/>  |          |        |
| For patients with prior NS5A inhibitor failure and cirrhosis, addition of weight-based ribavirin is recommended. | 12 weeks | IIa, C |

<sup>a</sup> For [decompensated cirrhosis](#), please refer to the appropriate section.

**Last update:** November 6, 2019